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Common variants in the hERG (KCNH2)
voltage-gated potassium channel are
associated with altered fasting and
glucose-stimulated plasma incretin and
glucagon responses
Line Engelbrechtsen1,2*† , Yuvaraj Mahendran1,2†, Anna Jonsson1, Anette Prior Gjesing1, Peter E. Weeke4,
Marit E. Jørgensen5,6, Kristine Færch6, Daniel R. Witte7, Jens J. Holst1,3, Torben Jørgensen8,9,10, Niels Grarup1,
Oluf Pedersen1, Henrik Vestergaard1,6, Signe Torekov1,3, Jørgen K. Kanters1,3 and Torben Hansen1
Abstract
Background: Patients with long QT syndrome due to rare loss-of-function mutations in the human ether-á-go-go-
related gene (hERG) have prolonged QT interval, risk of arrhythmias, increased secretion of insulin and incretins and
impaired glucagon response to hypoglycemia. This is caused by a dysfunctional Kv11.1 voltage-gated potassium channel.
Based on these findings in patients with rare variants in hERG, we hypothesized that common variants in hERG may also
lead to alterations in glucose homeostasis. Subsequently, we aimed to evaluate the effect of two common gain-of-
function variants in hERG (rs36210421 and rs1805123) on QT interval and plasma levels of glucagon-like peptide-1 (GLP-1),
glucose-dependent insulinotropic polypeptide (GIP), insulin and glucagon during an oral glucose tolerance test (OGTT).
We used two population-based cohorts for evaluation of the effect of common variants in hERG on QT-interval and
circulation levels of incretins, insulin and glucagon. The Danish population-based Inter99 cohort (n = 5895) was used to
assess the effect of common variants on QT-interval. The Danish ADDITION-PRO cohort was used (n = 1329) to study
genetic associations with levels of GLP-1, GIP, insulin and glucagon during an OGTT.
Results: Carriers of either the minor A-allele of rs36210421 or the minor G-allele of rs1805123 had ~ 2 ms shorter QT
interval per risk allele (p= 0.025 and p= 1.9 × 10− 7). Additionally, both variants were associated with alterations in
pancreatic and gut hormone release among carriers. The minor A- allele of rs36210421 was associated with increased GLP-
1 and decreased GIP response to oral glucose stimulation, whereas the minor G-allele of rs1805123 is associated with
decreased fasting plasma insulin and glucagon release. A genetic risk score combining the two gene variants revealed
reductions in glucose-stimulated GIP, as well as suppressed glucagon response to increased glucose levels during an OGTT.
Conclusions: Two common missense polymorphisms of the Kv11.1 voltage-gated hERG potassium channel are associated
with alterations in circulating levels of GIP and glucagon, suggesting that hERG potassium channels play a role in fasting
and glucose-stimulated release of GIP and glucagon.
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Background
Loss-of-function mutations in the human ether-á-go-go re-
lated (hERG) gene result in a dysfunctional Kv11.1 voltage-
gated potassium channel causing delayed cardiac repolariza-
tion, and long QT syndrome (LQTS) with increased risk of
cardiac arrhythmias and sudden death [1–4]. LQTS is char-
acterized by a prolongation of the QT-interval. The QT-
interval is the time between the start of the Q-wave and the
end of the T-wave in the ECG. The QT-interval reflects the
depolarization and repolarization of the ventricles in the
heart. Aside from cardiac muscle cells, voltage-gated hERG-
encoded Kv11.1 potassium channels are expressed in a num-
ber of tissues throughout the body including endocrine intes-
tinal K- and L-cells and pancreatic α- and β-cells [5–8]. This
has led to speculations that hERG channels may play a role
in secretion of hormones from endocrine cells [9].
Glucose homeostasis is tightly regulated by interaction
between glucose-regulating hormones from endocrine in-
testinal cells and pancreatic islet cells. A well-regulated
interplay between the incretins, glucagon-like peptide-1
(GLP-1) and gastric inhibitory polypeptide (GIP) from in-
testinal L- and K-cells, and the secretion of insulin and
glucagon from the pancreatic islets ensures glucose
homeostasis by limiting glucose excursions, by facilitating
uptake and storage of glucose during fed states, and by
regulating glucose production for glucose-dependent tis-
sues during fasting conditions. Secretion from the pancre-
atic islets cells and L-cells is determined by their electrical
activity which, among others, is regulated by different
types of voltage-gated potassium channels, and the hERG
channel is involved in repolarization of the membrane po-
tential [6–12].
Recently, Hyltén-Cavallius et al. [9] reported that pa-
tients with LQTS due to impaired function of the hERG-
encoded Kv11.1 potassium channel not only have alter-
ations in their cardiac conduction, but also exhibit in-
creased insulin, GLP-1 and GIP secretion with risk of
hypoglycemia, as well as decreased fasting and hypergly-
cemia induced levels of glucagon. Based on the findings
in carriers of rare variants, we hypothesized that com-
mon variants may also cause alterations in QT-interval
and in circulating levels of incretins, insulin and gluca-
gon levels. We selected non-synonymous coding variants
with a minor allele frequency > 3% in hERG (rs36210421
and rs1805123). We used data from two large cohorts;
the Inter99 cohort (n = 5487) to evaluate the effect of
common variants in hERG on QT-interval and the
ADDITION-PRO cohort (n = 1329) to evaluate the effect
on common variants on circulating plasma levels of
incretins, insulin and glucagon.
Methods
Populations
ADDITION-PRO is a cohort study of individuals at low
to high risk of type 2 diabetes, nested within the
population-based ADDITION-Denmark [13]. Overall,
1329 individuals were included - 708 normal glucose tol-
erance (NGT); 254 had isolated impaired fasting glucose
(IFG); 103 had isolated impaired glucose tolerance (IGT);
116 had both IFG and IGT, and 148 had screen detected
type 2 diabetes. Participants (48% females) had a mean
age of 66.3 ± 6.9 and a mean BMI of 27.1 ± 4.6. All individ-
uals who fasted < 8 h before the blood samples were taken,
or who used diabetes medication, or individuals with
already known diabetes were excluded (n = 22). Character-
istics of the ADDITION-PRO participants included in the
present study are given in Additional file 1: Table S1.
Inter99 is a population-based randomized intervention
study of 6784 participants aiming at preventing ischemic
heart disease by non-pharmacologic intervention
(ClinicalTrials.gov, NCT00289237). The Inter99 study has
been described in details previously [14]. We included
5487 individuals (51%) with a mean age of 46.2 ± 7.9 and a
BMI of 26.2 ± 4.5. More characteristics on the study par-
ticipants can be found in the Additional file 1: Table S1.
The ADDITION-PRO study was approved by the Eth-
ical Committee of the Central Denmark Region (journal
no. 20080229) and the Inter99 study was approved by the
Copenhagen County Ethical Committee (KA 98155) and
the National Board of Health. Both studies were con-
ducted in accordance with the principles of the Helsinki
Declaration. All study participants provided written in-
formed consent.
Biochemical measures
ADDITION-PRO and Inter99
Baseline venous blood samples were drawn after an over-
night fast (≥8 h). Participants underwent a standard 75 g
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oral glucose tolerance test (OGTT) with blood samples
drawn at 0, 30 and 120 min. Measurements of circulating
levels of glucose, insulin, GLP-1, GIP, and glucagon were
collected during the OGTT. Serum insulin was measured
by immunoassay (AutoDELFIA, Perkin Elmer, Massachu-
setts, United States). Plasma glucose was measured using
the Hitachi 912 system (Roche Diagnostics, Mannheim,
Germany) or the Vitros 5600 system (Ortho Clinical Diag-
nostics, Illkirch Cedex, France). Blood samples for the
measurement of GLP-1, GIP and glucagon were obtained
in tubes containing EDTA and put on ice immediately, be-
fore centrifugation at 4 °C. Plasma was stored at − 80 °C.
Total plasma GLP-1 (intact GLP-1 plus the metabolite
GLP-1 (9–36) amide), total plasma GIP (the sum of intact
GIP plus the metabolite GIP 3–42) and plasma glucagon
were determined using radio-immunological assays, as
previously described [15–17].
Electrocardiogram measures (ECG)
All ECGs were obtained on inclusion into the Inter99
cohort and were digitally recorded and stored in the
MUSE Cardiology Information System (GE Healthcare,
Wauwatosa, WI, USA) and processed using Marquette
12SL algorithm, version 21. ECG measurements were
assessed and analyzed digitally for heart rate and mean
QTc interval. QT- interval was used for assessment of
the impact of genetic variants on cardiac conduction.
QT interval was corrected for heart rate using Frideri-
cias formula (QTcF =QT / 3√RR) [18]. The RR interval
refers to the time between R waves.
Genetics
Non-synonymous coding variants in hERG were included
in this study. The variants were missense variants in hERG
with a minor allele frequency > 3% causing amino acid
substitutions with a significant effect on the hERG channel
function [19–21]. Two variants were chosen, rs36210421
and rs1805123. Previous functional in vitro and in vivo
studies [19–21] and population-based studies [20–25]
have demonstrated that the minor A-allele of rs36210421
(R1047L) and minor G-allele of rs1805123 (K897 T) have
gain-of-function effects on the hERG channel.
Addition-pro
We genotyped 1657 participants of the ADDITION-
PRO cohort applying the Illumina Infinium HumanCor-
eExome Beadchip (Illumina, San Diego, CA). We ex-
cluded individuals which were first degree relatives,
duplicates, ethnic outliers, or individuals who had ex-
treme inbreeding coefficients, mislabeled gender, or call
rate < 95%, leaving 1342 individuals who passed quality
control criteria [26]. A total of 1329 individuals had in-
formation on GLP1, GIP, glucagon, fasting glucose and
fasting serum insulin levels. Additional genotypes were
imputed (rs36210421) with high quality (proper_info >
0.95) into the 1000 genomes phase 1 panel using IM-
PUTE2. All variants were in Hardy Weinberg equilib-
rium (P > 0.05) [27].
INTER-99
In the Inter99 cohort, 6161 individuals were genotyped
with the Illumina Human Exome BeadChip v1.0 genotyp-
ing array (“the exome chip”), as previously described [28].
Statistical analyses
Statistical analyses were performed using R, version 3.1.3
(https://www.r-project.org/). The trapezoidal method
was used for calculation of total area under the curve
(AUC), incremental area under the curve (iAUC) for
GLP-1, GIP, insulin and glucagon. Calculations can be
found in Additional file 1. We used multiple linear re-
gression analysis to evaluate the association of QTcF,
fasting and stimulated levels of glucose, insulin, GLP-1,
GIP, and glucagon (as dependent variables) with the minor
A-allele of rs36210421 and the minor G-allele of rs1805123
SNPs/ GRS (as independent variable). Effect sizes (β coeffi-
cients) per copy of the risk alleles of the SNPs investigated
were estimated by linear regression analysis adjusted for
age, sex and BMI. In order to adjust for population stratifi-
cation, relatedness and to limit the type 1 error we calcu-
lated genome-wide principal components (PC) and
adjusted our model for the first three PCs along with other
covariates. P values < 0.05 were considered significant.
Genetic risk score (GRS)
To evaluate the combined effect of the two gene vari-
ants, rs36210421 and rs1805123, on QT-interval and
metabolic phenotypes, an additive model was used to
construct an unweighted genetic risk score. The GRS
was calculated by summation of the number of risk al-
leles across the two gene variants.
Results
The variants rs36210421 and rs1805123 in hERG were
present in individuals from the ADDITION-PRO cohort
with a minor allele frequency (MAF) of 3.4% (A-allele)
and 24% (G-allele) respectively, and in Inter99 with a
MAF of 3.1% and 22%, respectively. We found a low de-
gree of linkage disequilibrium between rs36210421 and
rs1805123 (R2 = 0.005 and D prime = 0.241). Demo-
graphic description of the Inter99 and the ADDITION-
PRO cohort can be seen in Additional file 1: Table S1.
Association of gene variants with duration of QT interval
The minor A-allele of rs36210421 (R1047L) and the minor
G-allele of rs1805123 (K897 T) were significantly associated
with shorter QTcF interval (β = − 2.4 ms, p = 0.016 and β =
− 2.1 ms, p = 1.3 × 10− 7) in the Inter99 study (Table 1).
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Associations of gene variants with fasting and stimulated
levels of glucose, insulin, GLP-1, GIP, and glucagon
In the ADDITION-PRO cohort the minor G-allele of
rs1805123 (K897 T) was significantly associated with
3.18 pmol/L (CI -5.87;-0.49)) lower fasting insulin (p =
0.025). The minor G-allele was associated with
0.95 pmol/L (− 1.52; − 0.38)) lower fasting glucagon (p =
0.003) (Additional file 1: Table S3). Additionally, we
found decreased glucagon AUC at 0–30 and 0–120 min
(β = − 2.73 (− 4.73, − 0.70), p = 0.009 and β = − 2.27 (−
4.25, − 0.24), p = 0.029, respectively) (Additional file 1:
Table S3). The minor A-allele of rs36210421 was associ-
ated with decreased fasting GIP (p = 0.04) and decreased
GIP120min (p = 0.04), as well as increased GLP-1 iAUC at
30 and 120 min (p = 0.02 and p = 0.04). In Inter99,
plasma glucose and serum insulin levels were not associ-
ated with the two gene variants (Table 1).
We calculated an unweighted genetic risk score (GRS),
assessing the additive effect of the minor A-allele of
rs36210421 and the minor G-allele of rs1805123 on meta-
bolic measures (Table 2, Fig. 1 and Additional file 1: Table
S2, and Fig. S2). The GRS was significantly associated with
lower fasting insulin (β=− 3.77 (− 6.36, − 1.18), p= 0.004),
lower fasting GIP (β=− 0.60 (− 1.16, − 0.04), p= 0.041) and
lower fasting glucagon (β=− 1.08 (− 1.78, − 0.38), p= 0.005).
Additionally, the GRS was significantly associated with GIP
AUC at 0–30 min was significantly decreased (β=− 1.96 (−
4.10, − 0.19), p= 0.044).The GRS was further associated with
a decrease in glucagon AUC at 0–30 min (β=− 2.27 (− 4.21,
− 0.29), p= 0.025), although not significant at 0–120 min (β
=− 1.85 (− 3.78, 0.12, p= 0.066). Additionally, there was
higher decremental glucagon AUC at 0–30 min, p= 0.011
and at 0–120 min, p= 0.003). Changes in plasma levels of
glucagon during an OGTT according to number of risk al-
leles are shown in Fig. 1 and Additional file 1: Figure S2.
Discussion
In this study, we demonstrate that common variants in
hERG, the minor A-allele of rs36210421 (R1047L) and
the minor G-allele of rs1805123 (K897 T), have pleotro-
pic effects, which not only cause shortening of QT-
interval, but also alterations in pancreatic and gut hor-
mone release among carriers. We report that the minor
A- allele of rs36210421 is associated with increased
GLP-1 and decreased GIP response to oral glucose
stimulation, whereas the minor G-allele of rs1805123 is
associated with decreased fasting plasma insulin and glu-
cagon release. Furthermore, we demonstrate that the
additive effect of both variants cause increased GIP se-
cretion and suppressed glucagon secretion, suggesting
that hERG potassium channels play an important role in
regulation of incretin and pancreatic hormone release.
We report that the minor A-allele of rs36210421 and
the minor G-allele of rs1805123 were associated with sig-
nificantly shorter QT interval among healthy individuals,
indicating a mild gain-of-function of both variants in car-
diac muscle cells, supporting the findings of previous
studies [19, 20, 23, 24]. The hERG ion channel is formed
by the KCNH2 protein that consists of six transmembrane
alpha helices, a pore helix and cytoplasmically located N-
and C-termini. The pore helix is thought to act as a
voltage-sensitive sensor [5]. The helices are formed by
bindings between amino acids and it is possible that
amino acids changes (caused by rs1805123 or rs36210421)
could lead to altered folding of the pore helix causing al-
terations in sensing or in opening/closing of the channel.
Hylten-Cavallius et al. recently reported that rare loss-
of-function mutations in hERG cause prolonged QT-
interval and increased GIP and GLP-1 secretion during
an OGTT [9]. We report that the two examined gain-of-
function hERG variants are associated with decreased
fasting GIP and GIP secretion during an OGTT, sup-
porting a role of hERG in GIP release from K-cells.
Furthermore, we assessed the effect of the variants in
hERG on glucose-stimulated insulin secretion. We re-
port that non-diabetic carriers of common variants in
hERG have lower fasting levels of insulin, but no alter-
ations in glucose-stimulated insulin release during an
Table 1 Association of variants (rs36210421 and rs1805123) with QT interval and metabolic changes in INTER99 cohort (n = 5487)
rs36210421 (MAF = 0.031) C > A rs1805123 (MAF = 0.22) T > G GRS
Trait β (95% CI) P β (95% CI) P β (95% CI) P
QTcF (ms) − 2.4 (− 4.31 – (− 0.47)) 0.016 −2.12 (− 2.91 – (− 1.33) 1.3E-07 −2.3 (− 3.05– (− 1.54) 2.2e-9
Fasting Glucose (mmol/L) 0.06 (− 0.02 – 0.14) 0.12 −0.01 (− 0.05–0.02) 0.84 −0.002 (− 0.03–0.03) 0.42
Glucose 30 min (mmol/L) 0.11 (− 0.07–0.29) 0.32 0.007 (− 0.07–0.08) 0.66 0.02 (−0.05–0.095) 0.43
Glucose 120 min (mmol/L) 0.05 (− 0.17–0.26) 0.76 −0.06 (− 0.15–0.03) 0.73 −0.05 (− 0.14–0.035) 0.88
Fasting Insulin (pmol/L) 0.57 (−2.07–3.22) 0.60 0.34 (− 0.75–1.44) 0.87 0.40 (− 0.64–1.45) 0.73
Insulin 30 min (pmol/L) 10.41 (− 7.90–28.72) 0.12 0.91 (− 6.67–8.49) 0.82 2.23 (− 4.77–9.67) 0.41
Insulin 120 min (pmol/L) 5.21 (− 15.8–26.22) 0.34 −6.86 (− 15.53–1.81) 0.32 −5.44 (− 13.71–2.84) 0.57
QTcF interval measured in milliseconds. β and P values were adjusted for age, sex and BMI. B and 95% is the effect size estimate using untransformed values. The
P values were obtained from the inverse normal transformation. GRS is the additive effect of both SNPs on QT interval. β, 95% and P values adjusted for age, sex
and BMI. P values < 0.05 are in bold
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OGTT in the ADDITION-PRO study. We did not repli-
cate lower fasting insulin levels among carriers of hERG
variants in the Inter99 study. Thus further studies are
needed to clarify whether common hERG variants have a
role in beta cell function.
The directionality of effect of the common gain-of-
function variants in hERG seems to be clear in K-cells
causing gain-of-function effect leading to decreased secre-
tion of GIP. It is more challenging to assess the effect of
the common variants in hERG on the alpha-cells in pan-
creas. Alpha-cells secrete glucagon secondary to action
potential firing and elevation of cytoplasmic Ca2+ concen-
tration [29]. These are regulated by fluctuations in glucose
and nutrient levels, and perhaps by autocrine and para-
crine control by insulin, GABA and Zn2+ secreted from
adjacent beta-cells and in particular by somatostatin from
the delta cells [30–32]. It is challenging to deduce how the
common variants in hERG influence all these factors.
Moreover, the variants in hERG may very well have diver-
ging effects in alpha-cells compared to K-cells.
In our study, we found lower fasting glucagon levels and
smaller decrements in glucose-stimulated glucagon secre-
tion in hERG gain-of-function carriers. The carriers did,
however, have normal glucose levels at fasting and during
oral glucose stimulation. Blocking of hERG channels in α-
cells has been shown to decrease glucagon secretion [6].
We therefore expected that the common gain-of-function
variants would cause alpha cells to increase glucagon se-
cretion. Carriers of the gain-of-function variants had lower
fasting levels of glucagon, but this might be a consequence
of the interplay with insulin and plasma glucose. The
mean glucagon levels during OGTT (at 30 and 120 min)
were not different from non-carriers, indicating that the
suppression of glucagon during glucose-stimulation was
probably intact. Supporting this hypothesis, Hardy et al.
previously demonstrated that at low glucose levels, block-
age of the hERG channel yields a initially stimulatory ef-
fect, but then depolarizes the alpha-cells sufficiently to
limit action potential firing and as a consequence less glu-
cagon is secreted [6]. hERG channels may therefore be
important regulators of glucagon secretion, but detailed in
vitro functional studies and/or hyperglycemic clamp stud-
ies with arginine stimulation in carriers of common gain-
of-function hERG variants are needed to pinpoint the
exact role of hERG channels in glucagon secretion.
Conclusions
We demonstrate that common amino acid polymorphisms
in the hERG (Kv11.1) voltage-gated potassium channel lead
to considerable alterations in plasma GIP and glucagon re-
lease, suggesting that voltage-gated hERG potassium chan-
nels may play an important role in the regulation of the
release of incretin and pancreatic hormones.
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